ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

National Cancer Act; White House announces Three Cancer Initiatives

November 1, 1996

Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint

June 27, 2014

Tacoma Hospital Finds Cancer DRGs Are Profitable

February 17, 1984

NCI Advisory Group, Other Cancer Meetings

July 25, 1986

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

July 25, 2014